405 related articles for article (PubMed ID: 28495495)
1. Translating in vitro ligand bias into in vivo efficacy.
Luttrell LM; Maudsley S; Gesty-Palmer D
Cell Signal; 2018 Jan; 41():46-55. PubMed ID: 28495495
[TBL] [Abstract][Full Text] [Related]
2. Biased agonism at the parathyroid hormone receptor: a demonstration of functional selectivity in bone metabolism.
Bohinc BN; Gesty-Palmer D
Mini Rev Med Chem; 2012 Aug; 12(9):856-65. PubMed ID: 22681253
[TBL] [Abstract][Full Text] [Related]
3. Biasing the parathyroid hormone receptor: relating in vitro ligand efficacy to in vivo biological activity.
Appleton KM; Lee MH; Alele C; Alele C; Luttrell DK; Peterson YK; Morinelli TA; Luttrell LM
Methods Enzymol; 2013; 522():229-62. PubMed ID: 23374189
[TBL] [Abstract][Full Text] [Related]
4. Arrestins in bone.
Bohinc BN; Gesty-Palmer D
Prog Mol Biol Transl Sci; 2013; 118():335-58. PubMed ID: 23764060
[TBL] [Abstract][Full Text] [Related]
5. β-arrestin-biased agonism at the parathyroid hormone receptor uncouples bone formation from bone resorption.
Bohinc BN; Gesty-Palmer D
Endocr Metab Immune Disord Drug Targets; 2011 Jun; 11(2):112-9. PubMed ID: 21476967
[TBL] [Abstract][Full Text] [Related]
6. β-Arrestin-biased signaling of PTH analogs of the type 1 parathyroid hormone receptor.
van der Lee MM; Verkaar F; Wat JW; van Offenbeek J; Timmerman M; Voorneveld L; van Lith LH; Zaman GJ
Cell Signal; 2013 Feb; 25(2):527-38. PubMed ID: 23159578
[TBL] [Abstract][Full Text] [Related]
7. Investigational parathyroid hormone receptor analogs for the treatment of osteoporosis.
Polyzos SA; Makras P; Efstathiadou Z; Anastasilakis AD
Expert Opin Investig Drugs; 2015 Feb; 24(2):145-57. PubMed ID: 25316089
[TBL] [Abstract][Full Text] [Related]
8. β-arrestin-selective G protein-coupled receptor agonists engender unique biological efficacy in vivo.
Gesty-Palmer D; Yuan L; Martin B; Wood WH; Lee MH; Janech MG; Tsoi LC; Zheng WJ; Luttrell LM; Maudsley S
Mol Endocrinol; 2013 Feb; 27(2):296-314. PubMed ID: 23315939
[TBL] [Abstract][Full Text] [Related]
9. 'Biasing' the parathyroid hormone receptor: a novel anabolic approach to increasing bone mass?
Gesty-Palmer D; Luttrell LM
Br J Pharmacol; 2011 Sep; 164(1):59-67. PubMed ID: 21506957
[TBL] [Abstract][Full Text] [Related]
10. Parathyroid hormone (PTH) and PTH-related peptide domains contributing to activation of different PTH receptor-mediated signaling pathways.
Cupp ME; Nayak SK; Adem AS; Thomsen WJ
J Pharmacol Exp Ther; 2013 Jun; 345(3):404-18. PubMed ID: 23516330
[TBL] [Abstract][Full Text] [Related]
11. Identification of key phosphorylation sites in PTH1R that determine arrestin3 binding and fine-tune receptor signaling.
Zindel D; Engel S; Bottrill AR; Pin JP; Prézeau L; Tobin AB; Bünemann M; Krasel C; Butcher AJ
Biochem J; 2016 Nov; 473(22):4173-4192. PubMed ID: 27623777
[TBL] [Abstract][Full Text] [Related]
12. Emergent biological properties of arrestin pathway-selective biased agonism.
Appleton KM; Luttrell LM
J Recept Signal Transduct Res; 2013 Jun; 33(3):153-61. PubMed ID: 23448506
[TBL] [Abstract][Full Text] [Related]
13. Noncanonical GPCR signaling arising from a PTH receptor-arrestin-Gβγ complex.
Wehbi VL; Stevenson HP; Feinstein TN; Calero G; Romero G; Vilardaga JP
Proc Natl Acad Sci U S A; 2013 Jan; 110(4):1530-5. PubMed ID: 23297229
[TBL] [Abstract][Full Text] [Related]
14. Fulfilling the Promise of "Biased" G Protein-Coupled Receptor Agonism.
Luttrell LM; Maudsley S; Bohn LM
Mol Pharmacol; 2015 Sep; 88(3):579-88. PubMed ID: 26134495
[TBL] [Abstract][Full Text] [Related]
15. Functional modulation of PTH1R activation and signaling by RAMP2.
Nemec K; Schihada H; Kleinau G; Zabel U; Grushevskyi EO; Scheerer P; Lohse MJ; Maiellaro I
Proc Natl Acad Sci U S A; 2022 Aug; 119(32):e2122037119. PubMed ID: 35914163
[TBL] [Abstract][Full Text] [Related]
16. Loss of Gsα in the Postnatal Skeleton Leads to Low Bone Mass and a Blunted Response to Anabolic Parathyroid Hormone Therapy.
Sinha P; Aarnisalo P; Chubb R; Poulton IJ; Guo J; Nachtrab G; Kimura T; Swami S; Saeed H; Chen M; Weinstein LS; Schipani E; Sims NA; Kronenberg HM; Wu JY
J Biol Chem; 2016 Jan; 291(4):1631-1642. PubMed ID: 26598522
[TBL] [Abstract][Full Text] [Related]
17. Endosomal signaling via cAMP in parathyroid hormone (PTH) type 1 receptor biology.
Peña KA; Savransky S; Lewis B
Mol Cell Endocrinol; 2024 Feb; 581():112107. PubMed ID: 37981188
[TBL] [Abstract][Full Text] [Related]
18. Ligand-selective dissociation of activation and internalization of the parathyroid hormone (PTH) receptor: conditional efficacy of PTH peptide fragments.
Sneddon WB; Magyar CE; Willick GE; Syme CA; Galbiati F; Bisello A; Friedman PA
Endocrinology; 2004 Jun; 145(6):2815-23. PubMed ID: 15016722
[TBL] [Abstract][Full Text] [Related]
19. NHERF1 regulates parathyroid hormone receptor membrane retention without affecting recycling.
Wang B; Bisello A; Yang Y; Romero GG; Friedman PA
J Biol Chem; 2007 Dec; 282(50):36214-22. PubMed ID: 17884816
[TBL] [Abstract][Full Text] [Related]
20. Delineation of a conserved arrestin-biased signaling repertoire in vivo.
Maudsley S; Martin B; Gesty-Palmer D; Cheung H; Johnson C; Patel S; Becker KG; Wood WH; Zhang Y; Lehrmann E; Luttrell LM
Mol Pharmacol; 2015 Apr; 87(4):706-17. PubMed ID: 25637603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
